Posted by Michael Wonder on 01 Apr 2022
ACE releases latest trance of drug guidances (April 2022)
1 April 2022 - The Agency for Clinical Effectiveness has released another batch of drug guidances.
The latest releases are for:
- Bevacizumab - cervical cancer
- Aflibercept, bevacizumab and ramucirumab - colorectal cancer
- Carbonic anhydrase inhibitors - glaucoma, ocular hypertension
- PARP inhibitors and bevacizumab - ovarian cancer
- Bevacizumab (biosimilar) - multiple cancers
